Jin Rong Jie·2026-01-30 09:13Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received a "Notice of Acceptance" from the National Medical Products Administration for the marketing authorization application of injectable fosnetupitant palonosetron, which is intended for the prevention of acute and delayed nausea and vomiting induced by moderately emetogenic anticancer chemotherapy in adult patients [1] Group 1 - The drug is a compound formulation that can simultaneously activate NK-1 and 5-HT3 receptors to inhibit the vomiting reflex [1] - Currently, there are no similar injectable products approved for marketing in China [1] - The total research and development investment for this project is approximately 247 million yuan [1]